Multibagger Pharma stock engaged in the marketing and distribution of active pharmaceutical ingredients (API) and finished formulations of pharmaceutical drugs jumped upto 12 percent in the day’s trade upon announcing an Interim Dividend and Bonus Issue in the ratio of 1:3. 

With a market capitalization of Rs. 1,132 Crores, the shares of Remus Pharmaceuticals Limited were trading at Rs. 7,690, up 11.26 percent from its previous day’s close price of Rs. 6,911.75. It has delivered multibagger returns of 370 percent in a year. 

The Board of Directors of Remus Pharmaceuticals Limited has approved and recommended the issuance of Bonus Shares to the equity shareholders of the Company in the ratio of 3: 1 where 3 new fully paid-up Equity Shares of Rs. 10 each will be given to each share held by shareholders of the company as on the record date. 

Note: If you want to learn Candlesticks and Chart Trading from Scratch, here’s the best book available on Amazon! Get the book now!

In Addition, it has declared a second interim dividend of Rs.4 per equity share having a face value of Rs. 10 each for the financial year 2023-24. It has fixed May 02, 2024, as the record date to determine the eligible shareholders of the company to receive the dividend. 

Remus Pharmaceuticals Limited is engaged in the marketing and distribution of active pharmaceutical ingredients (API) and finished formulations of pharmaceutical drugs, it also provides technical consulting services to various distributors for the preparation of reports on the dossiers of the products. 

It deals in drug forms like capsules, creams, eye drops, gels, infusions, inhalations, inhalers, injections, ointments, ophthalmic, oral gel, nail lacquers, nasal solutions, nasal spray, and many more. 

Its revenue from operations grew by 82 percent from Rs. 25 Crores in FY22 to Rs. 45 Crores in FY23, accompanied by profits of Rs. 3 Crores to Rs. 8 Crores. 

It has reported a return on equity (ROE) of 66.1 percent and a return on capital employed (ROCE) of 68.8 percent, it is making good returns on its equity and capital employed. 

Written by: Bharath K.S 


The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.